Snelle winst schreef:
[quote=geefhetstockjenogmaareenkeerdoor]
Dit aandeel is echt ongelooflijk.
Moet je echt even induiken.
Even in het kort:
1)RS gedaan: 16:1
Koers toen $6, nu $3.50
2) Hebben stock offering ingetrokken want: een dochterbedrijf kreeg FDA approval en DARA bezit
daar 1.6 aandelen van.
Lees maar:
www.globenewswire.com/newsroom/news.h...3) door deze IP ontvangt DARA 24 miljoen!!!
4) huidig marketcap is slechts 10 miljoen!!!!
5) Er staan maar 3 miljoen aandelen uit.
6) Directeur heeft in mei aandelen gekocht op de open markt:
biz.yahoo.com/e/100525/dara8-k.html7) Aandelen valued op $12.
Based on our analysis of the pipeline, we see DARA fairly valued at $12 per share. Our assumptions assume that DARA takes both KRN5500 and DB959 through phase IIb proof-of-concept and then out-licenses to a mid- to large-cap pharmaceutical company. Post-phase II products have been commanding upfront payments in the area of $25 million, followed by NDA filing and approval milestones north of $40 million, with another potential $200+ million in backend sales related milestones and royalties in the mid-teens.
Neuropathic pain candidate KRN5500 should be ready for a partnership post phase IIb data in 2011. Potential blockbuster type 2 diabetes candidate, DB959, is roughly one year behind, meaning that another lucrative partnership could follow in 2012.
Based on our analysis, KRN5500 alone is worth more than the entire market value. DB959 and several interesting preclinical candidates for metabolic and inflammatory disease round-out an impressive pipeline from which DARA should be able to extract value over the next several years. Therefore, we think upside is significant for this under-followed / under-valued story.
DARA Huge alert...SurgiVision (SRGV) Sees IPO Price of $13-$15/Share
June 25, 2010 1:46 PM EDT
SurgiVision (Nasdaq: SRGV) filed an amended registration statement with the U.S. Securities and Exchange Commission for an initial public offering of its common stock. The company plans to offer 2,500,000 common shares at a price range of $13 - $15 per ADS. The company plans to list on the Nasdaq Global Market under the symbol "SRGV."
The offering is being made through Canaccord Genuity and Rodman & Renshaw.
SurgiVision is a medical device company focused on the development and commercialization of technology that enables physicians to see inside the brain and heart using direct, intra-procedural magnetic resonance imaging, or MRI, guidance while performing minimally invasive procedures.
DARA own 1.6M shares at 15 bucks thats 24M
www.globenewswire.com/newsroom/news.h...Kortom, dit is me er eentje hoor.
[/quote]
Lekker bezig!! Stap je erin? Grt